HologicHOLX
About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Employees: 7,063
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 6 (+3) [Q2]
5% more capital invested
Capital invested by funds: $13.5B [Q1] → $14.2B (+$690M) [Q2]
2% more first-time investments, than exits
New positions opened: 102 | Existing positions closed: 100
0.49% more ownership
Funds ownership: 97.43% [Q1] → 97.92% (+0.49%) [Q2]
2% less funds holding
Funds holding: 692 [Q1] → 676 (-16) [Q2]
17% less repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 266
26% less call options, than puts
Call options by funds: $44.1M | Put options by funds: $59.5M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
RBC Capital Conor McNamara | 30%upside $87 | Outperform Upgraded | 6 Aug 2025 |
Morgan Stanley Tejas Savant | 3%upside $69 | Equal-Weight Maintained | 31 Jul 2025 |
UBS Elizabeth Garcia | 5%upside $70 | Neutral Maintained | 31 Jul 2025 |
Mizuho Anthony Petrone | 5%upside $70 | Outperform Maintained | 16 Jul 2025 |
Citigroup Patrick Donnelly | 20%upside $80 | Buy Upgraded | 9 Jul 2025 |
Financial journalist opinion
Based on 19 articles about HOLX published over the past 30 days









